Sara Silbert
YOU?
Author Swipe
View article: Pre-infusion risk factors predict severe infectious complications of CAR T-cell therapy in pediatric and adult patients with B-ALL
Pre-infusion risk factors predict severe infectious complications of CAR T-cell therapy in pediatric and adult patients with B-ALL Open
Background Despite the curative potential for chimeric antigen receptor (CAR) T-cells in B-cell acute lymphoblastic leukemia (B-ALL), efficacy can be limited by life-threatening adverse events such as severe infections. As immune effector …
View article: Quadriparesis after CD19 × CD22 bicistronic chimeric antigen receptor T cells for B‐cell acute lymphoblastic leukaemia
Quadriparesis after CD19 × CD22 bicistronic chimeric antigen receptor T cells for B‐cell acute lymphoblastic leukaemia Open
View article: “You Can Rest Knowing That We Know What You Want”—Longitudinal Advance Care Planning Discussions With Young Adults Receiving Hematopoietic Stem Cell Transplantation
“You Can Rest Knowing That We Know What You Want”—Longitudinal Advance Care Planning Discussions With Young Adults Receiving Hematopoietic Stem Cell Transplantation Open
Objective Young adults (YAs) undergoing hematopoietic stem cell transplantation (HSCT) often face significant transplant‐related morbidity and mortality. Advance care planning (ACP) discussions can provide YAs with the opportunity to addre…
View article: How I Approach Ethical Considerations for Pediatric Phase I CAR T‐Cell Trials
How I Approach Ethical Considerations for Pediatric Phase I CAR T‐Cell Trials Open
Phase I trials of chimeric antigen receptor (CAR) T cells have shown remarkable promise in pediatric B‐cell malignancies. Such outcomes have shifted expectations for other phase I CAR T‐cell trials to have high response rates. The juxtapos…
View article: Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia
Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia Open
Lineage switch (LS), defined as the immunophenotypic transformation of acute leukemia, has emerged as a mechanism of relapse after antigen-targeted immunotherapy, which is associated with dismal outcomes. Through an international collabora…
View article: Evolving strategies for addressing CAR T-cell toxicities
Evolving strategies for addressing CAR T-cell toxicities Open
View article: Development of ALL-Hematotox: predicting post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia
Development of ALL-Hematotox: predicting post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia Open
Immune effector cell–associated hematotoxicity (ICAHT) is a major B-cell targeted chimeric antigen receptor (CAR) T-cell related toxicity. Although ICAHT incidence and severity is documented in large B-cell lymphoma (LBCL), mantle cell lym…
View article: <i>CRLF2</i>-rearranged B-cell ALL with extramedullary lineage switch to AML following CD19-targeted therapy
<i>CRLF2</i>-rearranged B-cell ALL with extramedullary lineage switch to AML following CD19-targeted therapy Open
Lineage switch (LS) refers to the immunophenotypic transformation of one leukemia lineage to another (ie, lymphoid to myeloid) with retention of baseline genetics. This phenomenon was originally observed in infants with B-lymphoblastic leu…
View article: International Patients Paths to Chimeric Antigen Receptor T-Cell Therapy for B-ALL: No Two Journeys Are Alike
International Patients Paths to Chimeric Antigen Receptor T-Cell Therapy for B-ALL: No Two Journeys Are Alike Open
PURPOSE Chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) has a critical role in improving outcomes. Access to CAR T-cell therapy is limited for international patients fo…
View article: Weathering the storm when the end of the road is near: A qualitative analysis of supportive care needs during CAR T cell therapy in pediatrics
Weathering the storm when the end of the road is near: A qualitative analysis of supportive care needs during CAR T cell therapy in pediatrics Open
Background: Chimeric Antigen Receptor (CAR) T cell therapy provides promising outcomes in relapsed/refractory B Acute Lymphoblastic Leukemia (ALL) yet still carries high toxicities rates and relatively poor long-term survival. Efficacy has…
View article: “No Regrets:” The Pediatric Experience with Chimeric Antigen Receptor (CAR) T Cell Therapy
“No Regrets:” The Pediatric Experience with Chimeric Antigen Receptor (CAR) T Cell Therapy Open
View article: A comprehensive analysis of adverse events in the first 30 days of phase 1 pediatric CAR T-cell trials
A comprehensive analysis of adverse events in the first 30 days of phase 1 pediatric CAR T-cell trials Open
The tremendous success of chimeric antigen receptor (CAR) T cells in children and young adults (CAYAs) with relapsed/refractory B-cell acute lymphoblastic leukemia is tempered by toxicities such as cytokine release syndrome (CRS). Despite …
View article: Tandem hematopoietic stem cell transplant considerations in families with multiple siblings affected by DOCK8 deficiency
Tandem hematopoietic stem cell transplant considerations in families with multiple siblings affected by DOCK8 deficiency Open
View article: Fertility and CAR T-cells: Current practice and future directions
Fertility and CAR T-cells: Current practice and future directions Open
Chimeric antigen receptor (CAR) T-cells serve to overcome chemotherapeutic resistance and have been proven to be highly effective in B-cell hematologic malignancies. Although initial use has been in patients with multiply relapsed/refracto…
View article: CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR
CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR Open
Remission durability following single-antigen targeted chimeric antigen receptor (CAR) T-cells is limited by antigen modulation, which may be overcome with combinatorial targeting. Building upon our experiences targeting CD19 and CD22 in B…
View article: How Should We Determine the Value of CAR T-Cell Therapy?
How Should We Determine the Value of CAR T-Cell Therapy? Open
In 2017, the US Food and Drug Administration approved the first chimeric antigen receptor (CAR) T-cell therapies for patients with relapsed or refractory B-cell leukemia and selected B-cell lymphomas. This novel form of cellular immunother…